A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Summary

* To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study. * To investigate efficacy of SPM 962 in an exploratory manner.

Timeline

Start

2009-10

Primary completion

2012-06

Completion

2012-06

Drugs

Indications